Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3541860 in moderately to severely active Rheumatoid Arthritis
NCT06859294Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LY3541860 in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started Mar 2025; status: terminated.
02
Drugs
LY3541860
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06859294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859294.